Targeting RAF dimers in RAS mutant tumors: From biology to clinic
RAS mutations occur in approximately 30% of tumors worldwide and have a poor prognosis due to limited therapies. Covalent targeting of KRAS G12C has achieved significant success in recent years, but there is still a lack of efficient therapeutic approaches for tumors with non-G12C KRAS mutations. A...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2024-05-01
|
| Colecção: | Acta Pharmaceutica Sinica B |
| Assuntos: | |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S221138352400056X |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|